Boron-containing compounds (BCC) have emerged as important pharmacophores. To date,
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …

The β-lactams are the most widely used antibacterial agents worldwide. These antibiotics, a
group that includes the penicillins and cephalosporins, are covalent inhibitors that target …

Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) present a global clinical
threat, as these β-lactamases confer resistance to carbapenems and oxyimino …

QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates.
The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere …

Klebsiella pneumoniae is an important multidrug-resistant (MDR) pathogen that can cause a
range of infections in hospitalized patients. With the growing use of antibiotics, MDR K …

Metallo-β-lactamase (MBL) production in Gram-negative bacteria is an important contributor
to β-lactam antibiotic resistance. Combining β-lactams with β-lactamase inhibitors (BLIs) is a …

Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a
major global health concern associated with the emergence of new β-lactamases (BLAs) as …

The use of β‐lactamase inhibitors in combination with β‐lactam antibiotics is an emerging
area in drug discovery. This strategy allows the restoration of the therapeutic efficacy of …

Background Due to antibiotic overuse, numerous organisms have evolved multidrug
resistance, a global health crisis. Klebsiella pneumoniae (K. pneumoniae) causes …

Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens
their widespread use. Bicyclic boronates show promise as clinically useful, dual-action …